Leuprolide vs Melanotan II
Side-by-side comparison of key properties, dosing, and research.
Sexual Health & Libido
LeuprolideSexual Health & Libido
Melanotan II- Summary
- Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
- Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
- Half-Life
- ~3 hours (SC/IM), but depot formulations last 1–12 months
- 1–2 hours
- Admin Route
- SubQ, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
- 0.25–0.5 mg
- Frequency
- Per depot schedule
- Once daily
- Key Benefits
- Medical: reduces testosterone in prostate cancer
- Medical: suppresses estrogen in endometriosis and uterine fibroids
- Medical: delays precocious puberty
- Research: testosterone rebound effect after short course
- Transgender care: hormone suppression in adolescents
- Research: hormonal re-sensitization protocols
- Promotes skin tanning and melanin production
- Reduces UV exposure needed to tan
- Enhances libido and sexual function
- May suppress appetite
- Faster, deeper tan development
- Longer-lasting tan maintenance
- Potential photoprotective effects
- Side Effects
- Hot flashes (with testosterone suppression)
- Decreased libido and erectile dysfunction
- Initial testosterone flare (first 1–2 weeks)
- Bone density loss with long-term use
- +3 more
- Nausea (very common, especially in first days)
- Facial flushing
- Spontaneous erections in men
- Darkening or changes in existing moles (monitor closely)
- +3 more
- Stacks With
- —
- —